Figure 1 | Modern Pathology

Figure 1

From: Poor outcome of hepatocellular carcinoma with stemness marker under hypoxia: resistance to transarterial chemoembolization

Figure 1

Expression of K19, epithelial cell adhesion molecule (EpCAM), and carbonic anhydrase-IX (CAIX) in HCCs and the response to TACC (cohort 1, n=14). (a) Representative cases of K19-, EpCAM-, and CAIX-negative HCC and K19-, EpCAM-, and CAIX-positive HCC and the proportion of residual tumor in resected specimens after TACC. (b) The expression status of K19, EpCAM, and CAIX, response to TACC, and outcome in individual HCC patients with biopsy-resection-matched tissue. The outcome was measured as recurrence within 2 years, extrahepatic recurrence within 2 years, and death within 5 years. (c) Comparison of TACC response between HCCs expressing at least one of K19, EpCAM, or CAIX (n=6) and HCCs expressing none of three markers (n=8) in biopsy. *P<0.05. HCC, hepatocellular carcinoma; TACE, transarterial chemoembolization.

Back to article page